Skip to main content
main-content
Erschienen in: Der Pathologe 6/2021

13.10.2021 | PSA-Screening | CME

Das lokalisierte Prostatakarzinom

verfasst von: Prof. Dr. V. W. Sailer, S. Perner, P. Wild, J. Köllermann

Erschienen in: Der Pathologe | Ausgabe 6/2021

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Prostatakarzinom ist der häufigste nichtkutane maligne Tumor des Manns. Einer der stärksten prognostischen Parameter im Hinblick auf das rezidivfreie und das Gesamtüberleben ist das Gleason-Grading, das in den letzten Jahren zahlreiche Modifikationen und Präzisierungen erfahren hat. Der Gleason-Score, erhoben an der prätherapeutischen Stanzbiopsie, hat einen erheblichen Einfluss auf das klinische Management der Patienten. Dies spiegelt sich auch in den Empfehlungen der S3-Leitlinie zum Prostatakarzinom wider, die sich vielfach an den histopathologischen Befunden der Stanzbiopsie und am Gleason-Score orientieren. In diesem zweiten Teil der zweiteiligen CME-Fortbildung zur Prostatapathologie wird auf die Diagnose der azinären und duktalen Prostatakarzinome, die aktuelle Befunderstellung an der Stanzbiopsie, das neuroendokrine Prostatakarzinom sowie prognostische Tests eingegangen. Zudem enthält dieser Beitrag einen Exkurs zu Urothelkarzinomen der prostatischen Harnröhre.
Zugang erhalten Sie mit:
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
2.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB et al (2016) The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244–252 CrossRefPubMedCentral Epstein JI, Egevad L, Amin MB et al (2016) The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244–252 CrossRefPubMedCentral
3.
Zurück zum Zitat Perner S, Sailer V‑W (2020) Histopathologische Diagnostik der Prostatastanzbiopsie. Springer, Berlin, Heidelberg CrossRef Perner S, Sailer V‑W (2020) Histopathologische Diagnostik der Prostatastanzbiopsie. Springer, Berlin, Heidelberg CrossRef
4.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr., Amin MB et al (2005) The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242 CrossRefPubMedCentral Epstein JI, Allsbrook WC Jr., Amin MB et al (2005) The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242 CrossRefPubMedCentral
5.
Zurück zum Zitat Gordetsky J, Epstein J (2016) Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 11:25 CrossRefPubMedCentral Gordetsky J, Epstein J (2016) Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 11:25 CrossRefPubMedCentral
6.
Zurück zum Zitat Zhou M, Li J, Cheng L et al (2015) Diagnosis of “poorly formed glands” Gleason pattern 4 prostatic adenocarcinoma on needle biopsy: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Surg Pathol 39:1331–1339 CrossRefPubMedCentral Zhou M, Li J, Cheng L et al (2015) Diagnosis of “poorly formed glands” Gleason pattern 4 prostatic adenocarcinoma on needle biopsy: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Surg Pathol 39:1331–1339 CrossRefPubMedCentral
7.
Zurück zum Zitat Kweldam CF, Nieboer D, Algaba F et al (2016) Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology 69:441–449 CrossRefPubMedCentral Kweldam CF, Nieboer D, Algaba F et al (2016) Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology 69:441–449 CrossRefPubMedCentral
8.
Zurück zum Zitat Hollemans E, Verhoef EI, Bangma CH et al (2020) Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Mod Pathol 33:1618–1625 CrossRefPubMedCentral Hollemans E, Verhoef EI, Bangma CH et al (2020) Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Mod Pathol 33:1618–1625 CrossRefPubMedCentral
10.
Zurück zum Zitat van Leenders G, van Der Kwast TH, Grignon DJ et al (2020) The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87–e99 CrossRefPubMedCentral van Leenders G, van Der Kwast TH, Grignon DJ et al (2020) The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87–e99 CrossRefPubMedCentral
11.
Zurück zum Zitat Fajardo DA, Miyamoto H, Miller JS et al (2011) Identification of Gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology. Am J Surg Pathol 35:1706–1711 CrossRefPubMedCentral Fajardo DA, Miyamoto H, Miller JS et al (2011) Identification of Gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology. Am J Surg Pathol 35:1706–1711 CrossRefPubMedCentral
12.
Zurück zum Zitat Offermann A, Hupe MC, Joerg V et al (2020) Reports of prostate needle biopsies-what pathologists provide and urologists want. Urologe A 59:461–468 CrossRefPubMedCentral Offermann A, Hupe MC, Joerg V et al (2020) Reports of prostate needle biopsies-what pathologists provide and urologists want. Urologe A 59:461–468 CrossRefPubMedCentral
13.
Zurück zum Zitat WHO (2016) WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn. WHO, Lyon WHO (2016) WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn. WHO, Lyon
15.
Zurück zum Zitat Epstein JI, Amin MB, Beltran H et al (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756–767 CrossRefPubMedCentral Epstein JI, Amin MB, Beltran H et al (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756–767 CrossRefPubMedCentral
16.
Zurück zum Zitat Zhou M (2018) High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol 31:S71–79 CrossRefPubMedCentral Zhou M (2018) High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol 31:S71–79 CrossRefPubMedCentral
17.
19.
20.
Zurück zum Zitat Epstein JI, Egevad L, Humphrey PA et al (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the international society of urologic pathology consensus conference. Am J Surg Pathol 38:e6–e19 CrossRefPubMedCentral Epstein JI, Egevad L, Humphrey PA et al (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the international society of urologic pathology consensus conference. Am J Surg Pathol 38:e6–e19 CrossRefPubMedCentral
21.
Zurück zum Zitat Rubin MA, Zhou M, Dhanasekaran SM et al (2002) Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662–1670 CrossRefPubMedCentral Rubin MA, Zhou M, Dhanasekaran SM et al (2002) Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662–1670 CrossRefPubMedCentral
23.
Zurück zum Zitat Gandhi JS, Smith SC, Paner GP et al (2020) Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate: a survey of genitourinary subspecialists. Am J Surg Pathol 44:673–680 CrossRefPubMedCentral Gandhi JS, Smith SC, Paner GP et al (2020) Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate: a survey of genitourinary subspecialists. Am J Surg Pathol 44:673–680 CrossRefPubMedCentral
25.
Zurück zum Zitat Seipel AH, Wiklund F, Wiklund NP et al (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462:429–436 CrossRefPubMedCentral Seipel AH, Wiklund F, Wiklund NP et al (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462:429–436 CrossRefPubMedCentral
26.
Zurück zum Zitat Brinker DA, Potter SR, Epstein JI (1999) Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 23:1471–1479 CrossRefPubMedCentral Brinker DA, Potter SR, Epstein JI (1999) Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 23:1471–1479 CrossRefPubMedCentral
27.
Zurück zum Zitat Copeland JN, Amin MB, Humphrey PA et al (2002) The morphologic spectrum of metastatic prostatic adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. Am J Clin Pathol 117:552–557 CrossRefPubMedCentral Copeland JN, Amin MB, Humphrey PA et al (2002) The morphologic spectrum of metastatic prostatic adenocarcinoma to the lung: special emphasis on histologic features overlapping with other pulmonary neoplasms. Am J Clin Pathol 117:552–557 CrossRefPubMedCentral
28.
Zurück zum Zitat Meeks JJ, Zhao LC, Cashy J et al (2012) Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the surveillance, epidemiology, and end results program. BJU Int 109:831–834 CrossRefPubMedCentral Meeks JJ, Zhao LC, Cashy J et al (2012) Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the surveillance, epidemiology, and end results program. BJU Int 109:831–834 CrossRefPubMedCentral
29.
Zurück zum Zitat Tu SM, Reyes A, Maa A et al (2002) Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94:2610–2617 CrossRefPubMedCentral Tu SM, Reyes A, Maa A et al (2002) Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94:2610–2617 CrossRefPubMedCentral
30.
Zurück zum Zitat Seipel AH, Delahunt B, Samaratunga H et al (2014) Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology 65:216–227 CrossRefPubMedCentral Seipel AH, Delahunt B, Samaratunga H et al (2014) Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology 65:216–227 CrossRefPubMedCentral
31.
Zurück zum Zitat Bostwick DG, Kindrachuk RW, Rouse RV (1985) Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 9:595–609 CrossRefPubMedCentral Bostwick DG, Kindrachuk RW, Rouse RV (1985) Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 9:595–609 CrossRefPubMedCentral
32.
Zurück zum Zitat Lee TK, Miller JS, Epstein JI (2010) Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 42:319–324 CrossRefPubMedCentral Lee TK, Miller JS, Epstein JI (2010) Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 42:319–324 CrossRefPubMedCentral
34.
Zurück zum Zitat Puca L, Vlachostergios PJ, Beltran H (2019) Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med 9(2):a30593 CrossRefPubMedCentral Puca L, Vlachostergios PJ, Beltran H (2019) Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med 9(2):a30593 CrossRefPubMedCentral
35.
Zurück zum Zitat Mosquera JM, Beltran H, Park K et al (2013) Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15:1–10 CrossRefPubMedCentral Mosquera JM, Beltran H, Park K et al (2013) Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15:1–10 CrossRefPubMedCentral
37.
Zurück zum Zitat Kaur H, Samarska I, Lu J et al (2020) Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: molecular characterization and clinical significance. Prostate 80:1012–1023 CrossRefPubMedCentral Kaur H, Samarska I, Lu J et al (2020) Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: molecular characterization and clinical significance. Prostate 80:1012–1023 CrossRefPubMedCentral
39.
Zurück zum Zitat Agrawal S, Lacy JM, Bagga H et al (2017) Secondary urethral malignancies following prostate brachytherapy. Urology 110:172–176 CrossRefPubMedCentral Agrawal S, Lacy JM, Bagga H et al (2017) Secondary urethral malignancies following prostate brachytherapy. Urology 110:172–176 CrossRefPubMedCentral
40.
Zurück zum Zitat Paner GP, Montironi R, Amin MB (2017) Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol 24:113–127 CrossRefPubMedCentral Paner GP, Montironi R, Amin MB (2017) Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol 24:113–127 CrossRefPubMedCentral
42.
Zurück zum Zitat Wittekind C (2020) TNM Klassifikation maligner Tumoren. Wiley-VCH, Wittekind C (2020) TNM Klassifikation maligner Tumoren. Wiley-VCH,
43.
Zurück zum Zitat Janisch F, Abufaraj M, Fajkovic H et al (2019) Current disease management of primary urethral carcinoma. Eur Urol Focus 5:722–734 CrossRefPubMedCentral Janisch F, Abufaraj M, Fajkovic H et al (2019) Current disease management of primary urethral carcinoma. Eur Urol Focus 5:722–734 CrossRefPubMedCentral
Metadaten
Titel
Das lokalisierte Prostatakarzinom
verfasst von
Prof. Dr. V. W. Sailer
S. Perner
P. Wild
J. Köllermann
Publikationsdatum
13.10.2021
Verlag
Springer Medizin
Erschienen in
Der Pathologe / Ausgabe 6/2021
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-021-00997-8